News Aradigm Corporation

Equities

ARDMQ

US0385054004

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		+6.73%	-25.81%

2020	Aradigm Corporation Went Out of Business	CI
2020	Modified Combined Liquidation Plan and Discosure Statement Approved for Aradigm Corporation	CI

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Aradigm Corporation Went Out of Business	20-06-29	CI
ARADIGM CORP : Other Events, Financial Statements and Exhibits (form 8-K)	20-06-15	AQ
Modified Combined Liquidation Plan and Discosure Statement Approved for Aradigm Corporation	20-06-12	CI
ARADIGM CORP : Other Events (form 8-K)	20-06-04	AQ
ARADIGM CORP : Other Events, Financial Statements and Exhibits (form 8-K)	20-04-30	AQ
Revised Disclosure Statement Conditionally Approved for Aradigm Corporation	20-04-27	CI
ARADIGM CORP : Other Events (form 8-K)	20-04-13	AQ
Combined Liquidation Plan and Disclosure Statement Filed by Aradigm Corporation	20-04-08	CI
Aradigm : Announces Sale of Assets to Grifols, S.A.	20-04-06	AQ
ARADIGM CORP : Other Events, Financial Statements and Exhibits (form 8-K)	20-04-03	AQ
Grifols, S.A. completed the acquisition of Assets and Intellectual Property of Lipoquin, Free Ciprofloxacin, Apulmiq from Aradigm Corporation (OTCPK:ARDM.Q).	20-03-30	CI
Motion for Asset Sale Approved for Aradigm Corporation	20-03-30	CI
ARADIGM CORP : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)	20-03-09	AQ
Bidding Procedure Approved for Aradigm Corporation	20-03-09	CI
Aradigm : Announces Entering into an Asset Purchase Agreement with Grifols, S.A	20-02-24	AQ
ARADIGM CORP : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	20-02-21	AQ
Motion for Asset Sale Filed by Aradigm Corporation	20-02-20	CI
Grifols, S.A. entered into an asset purchase agreement to acquire Assets and Intellectual Property of Lipoquin, Free Ciprofloxacin, Apulmiq from Aradigm Corporation (OTCPK:ARDM.Q) for $6.3 million.	20-02-20	CI
Second Motion for Exclusivity Period Extension Approved For Aradigm Corporation	19-11-05	CI
Aradigm Corporation Announces Withdrawal of European Marketing Authorization Application for Linhaliq	19-10-30	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Aradigm Corporation

Equities

ARDMQ

US0385054004

Summary

Filters